Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
383M
-
Number of holders
-
305
-
Total 13F shares, excl. options
-
933M
-
Shares change
-
-345M
-
Total reported value, excl. options
-
$311M
-
Value change
-
-$135M
-
Put/Call ratio
-
2.13
-
Number of buys
-
111
-
Number of sells
-
-173
-
Price
-
$0.33
Significant Holders of RECURSION PHARMACEUTICALS, INC. - Common Stock (DNA) as of Q2 2024
383 filings reported holding DNA - RECURSION PHARMACEUTICALS, INC. - Common Stock as of Q2 2024.
RECURSION PHARMACEUTICALS, INC. - Common Stock (DNA) has 305 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 933M shares
.
Largest 10 shareholders include VIKING GLOBAL INVESTORS LP (143M shares), VANGUARD GROUP INC (139M shares), BAILLIE GIFFORD & CO (134M shares), Anchorage Capital Group, L.L.C. (69.9M shares), BlackRock Inc. (42M shares), TWO SIGMA ADVISERS, LP (31.4M shares), Legal & General Group Plc (26.9M shares), GLENVIEW CAPITAL MANAGEMENT, LLC (26.5M shares), SB INVESTMENT ADVISERS (UK) LTD (24.4M shares), and ARK Investment Management LLC (23.9M shares).
This table shows the top 305 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.